SERPINB3 and neoplasm: Abnormal serum tumor marker levels for NSE were seen in 13 (27.1%) of 48, proGRP in 3 (17.6%) of 17, CA125 in 6 (13.3%) of 45, CA19-9 in 5 (11.9%) of 42, CEA in 4 (7.1%) of 56, SCC in 4 (7.1%) of 56, AFP in 0 (0%) of 5, and CYFRA in 0 (0%) of 2 patients.